Treatment of pain by targeting NR4A1 (US12611393B2)
The present invention involves a method of treating pain. The method treats a patient having post-operative pain or chemotherapy induced neuropathic pain, and it involves a) assessing the patient to determine if they are experiencing post-operative pain or chemotherapy induced neuropathic pain, and if such pain is diagnosed; b) administering to the patient a therapeutically effective amount of an agonist for the nuclear receptor subfamily 4, group A, member 1 (NR4A1). In one embodiment, the agonist is selected from the group consisting of Cytosporone B, Ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)-phenyl] acetate (TMPA), 1,3,7-trihydroxy-2,4-diprenylxanthone (CCE9), 1-(3,4,5-trihydroxyphenyl)-nonan-1-one (THPN), DIM-C-pPhOCH3 (C-DIM-5), 1,1-bis(3′-indolyl)-1-(phenyl)methane (DIM-C-Ph) and 1,1-bis(3′-indolyl)-1-(p-anisyl)methane (DIM-C-pPhOCH3).
About University of Cincinnati Medical Center
University of Cincinnati Medical Center is an academic medical center and flagship hospital for UC Health, serving as the primary adult teaching site for the University of Cincinnati. As a large tertiary and quaternary care provider on an urban health campus, it offers ready access to diverse patient populations and co-located university research facilities. A dedicated clinical research infrastructure supports industry sponsors with feasibility assessments, contracting, IRB coordination, and data services, leveraging integrated EHR resources, imaging, and biorepositories. Research activity is supported by competitive federal funding, including the National Institutes of Health and other U.S. agencies. Commercialization is facilitated through the university’s technology transfer office and innovation programs that guide IP protection, licensing, and startup formation.
delivered to your inbox.